Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which:

X is C_{1-6}alkyl or OR^6;

Y is ~~selected from~~ hydrogen~~, halogen, CN, nitro, SO_2R^3, OR^4, SR^4, SOR^3, $SO_2NR^4R^5$, $CONR^4R^5$, NR^4R^5, $NR^6SO_2R^3$, $NR^6CO_2R^6$, NR^6COR^3, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl or C_{1-6}alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, OR^6 and NR^6R^7, $S(O)_nR^6$; n is 0, 1 or 2~~;

Z is phenyl optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, OH, SH, nitro, COR^9, CO_2R^6, SO_2R^9, OR^9, SR^9, SOR^9, $SO_2NR^{10}R^{11}$, $CONR^{10}R^{11}$, $NR^{10}R^{11}$, $NHSO_2R^9$, $NR^9SO_2R^9$, $NR^6CO_2R^6$, $NHCOR^9$, NR^9COR^9, $NR^6CONR^4R^5$, $NR^6SO_2NR^4R^5$, aryl,
C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl or C_{1-6}alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C_3-C_7 cycloalkyl, OR^6, NR^6R^7, $S(O)_nR^6$, $CONR^6R^7$, NR^6COR^7, $SO_2NR^6R^7$ and $NR^6SO_2R^7$.

R^1 and R^2 independently represent a hydrogen atom, halogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl or a C_{1-6}alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen,
C_3-C_7 cycloalkyl, NR^6R^7, OR^6, $S(O)_nR^6$;

R^3 represents C_3-C_7 cycloalkyl or C_{1-6}alkyl which may be optionally substituted by one or more substituents independently selected from halogen, C_3-C_7 cycloalkyl, OR^6 and NR^6R^7, $S(O)_nR^6$, $CONR^6R^7$, NR^6COR^7,$SO_2NR^6R^7$ and $NR^6SO_2R^7$;

R^4 and R^5 independently represent hydrogen, C_3-C_7 cycloalkyl or C_{1-6}alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C_3-C_7 cycloalkyl, OR^6 and NR^6R^7, $S(O)_nR^6$, $CONR^6R^7$, NR^6COR^7,$SO_2NR^6R^7$ and $NR^6SO_2R^7$;

R^6 and R^7 independently represents a hydrogen atom or C_1-C_6 alkyl;

R^8 is hydrogen, C_{1-4} alkyl, -COC_1-C_4 alkyl, CO_2C_1-C_4alkyl or $CONR^6C_1$-C_4alkyl;

R^9 represents aryl, C_3-C_7 cycloalkyl or C_{1-6}alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C_3-C_7 cycloalkyl, aryl, OR^6 and NR^6R^7, $S(O)_nR^6$, $CONR^6R^7$, NR^6COR^7, $SO_2NR^6R^7$ and $NR^6SO_2R^7$;

R^{10} and R^{11} independently represent aryl, hydrogen, C_3-C_7 cycloalkyl or C_{1-6}alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C_3-C_7 cycloalkyl, aryl, OR^6 and NR^6R^7, $S(O)_nR^6$, $CONR^6R^7$, NR^6COR^7, $SO_2NR^6R^7$ and $NR^6SO_2R^7$.

2. (Previously Presented) A compound according to claim 1 in which R^1 and R^2 independently represent a hydrogen atom, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_7 cycloalkyl or a C_{1-6}alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C_3-C_7 cycloalkyl, NR^6R^7, OR^6, $S(O)_nR^6$.

3. (Previously presented) A compound according to claim 1 in which X is C_{1-4}alkyl or C_{1-4}alkoxy.

4. (Cancelled)

5. (Cancelled)

6. (Previously Presented) A compound according to claim 1 in which Z is substituted by one or more substituents independently selected from halogen, C_{1-3}alkyl, cyano and SO_2R^9.

7. (Previously presented) A compound according to claim 1 in which R^1 and R^2 are both hydrogen or one is hydrogen and the other is C_{1-3} alkyl.

8. (Currently Amended) A compound according to claim 1 selected from:
[(5-Methylbiphenyl-2-yl)oxy]acetic acid,
{[5-Ethyl-4'-(methylsulfonyl)biphenyl-2-yl]oxy}acetic acid,
{[4'-(Ethylsulfonyl)-5-methoxybiphenyl-2-yl]oxy}acetic acid,

~~[[4-Chloro-4'-(ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,~~
[[4'-(Ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,
2-[[3'-Cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,
2-[[2'-Fluoro-5'-cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,
and pharmaceutically acceptable salts thereof.

Claims 9-11 (Cancelled)

12. (Previously presented) A method for the therapeutic treatment of asthma or rhinitis in a patient suffering from asthma or rhinitis, which comprises administering to the ~~a~~ patient suffering from asthma or rhinitis a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1.

13. (Previously presented) A compound according to claim 2 in which X is C_{1-4}alkyl or C_{1-4}alkoxy.

14. (Cancelled)

15. (Cancelled)

16. (Previously presented) A compound according to claim 2 in which Z substituted by one or more substituents independently selected from halogen, C_{1-3}alkyl, cyano and SO_2R^9.

17. (Previously presented) A compound according to claim 2 in which R^1 and R^2 are both hydrogen or one is hydrogen and the other is C_{1-3} alkyl.

18. (Previously presented) A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent, or carrier.

19. (Previously presented) A method of producing a CRTh2 receptor inhibitory effect in a patient, which comprises administering to the patient an effective amount of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof.